

# Aim for the stars, reach the moon?

## A simple strategy to improve additional benefit outcomes in Germany?

Richard Macaulay,  
Anne Jakel, Ikhl as Kasli,  
Andrea Berardi, and  
George Duo Wang

Parexel® International,  
London, UK  
richard.macaulay@parexel.com

### Background

- New pharmacological therapies in Germany can be subject to an early benefit assessment (EBA) upon launch:
  - If the Federal Joint Committee (G-BA) deem a new therapy offers no additional benefit, it cannot negotiate for a price premium
- The Institute for Quality and Efficiency in Health Care (IQWiG) conducts an initial assessment, followed by a final resolution by G-BA
- This research evaluates any correlation between the additional benefit that manufacturers claim, and the benefit that IQWiG, and G-BA grant

### Methods

- All EBAs completed between 01/01/2016 to 30/05/2019 were extracted from the G-BA website alongside corresponding IQWiG assessments, and manufacturer submissions and key information compared
- For extracted outcome data, the focus was the subgroup of greatest additional benefit
- Statistical analyses were conducted using Chi-squared tests and logistic regression models

### Results

Figure 1. Comparison of additional benefit claimed by manufacturers versus those reported by IQWiG and G-BA





Figure 2: Correlation of additional benefit claimed by manufacturers versus those reported by IQWiG and G-BA



- Both IQWiG and G-BA were significantly likely to report a lower extent of additional benefit than manufacturer requested (134/172 and 153/206; p<0.01 for both)
- Manufacturers requesting lesser levels of benefits increased the odds of both G-BA and IQWiG recognising no additional benefits, with IQWiG less so than G-BA (Wald tests: G-BA=11.4, p=0.077; IQWiG=26.1, p<0.01, respectively)

### Conclusions

- Manufacturers requesting lower additional benefits obtain less favourable EBAs from both IQWiG and G-BA
- Further research is needed to identify whether manufacturers request greater additional benefit for drugs with a stronger supportive data package or whether manufacturer requests for additional benefit independently impact G-BA and IQWiG decision-making

